LATS2 (Large Tumor Suppressor Kinase 2)

Comparative analyses with other gallbladder carcinoma subtypes revealed GBASC to have distinct clinical phenotypes, molecular alterations, functional characteristics, and enriched signaling pathways. Moreover, there is an urgent need for standardized treatment protocols.

Fusion-based ELN 2022 reclassified most intermediate-risk patients. RNA-seq enhances prognostic assessment in AML-NK.

In the two external GEO (GSE71014 and GSE6891) datasets, area under the curve values of 1, 3, 5 years were 0.847, 0.857, 0.822, and 0.830, 0.863, 0.891 respectively. Our seven signature genes containing risk-scoring model performed excellently in evaluating the OS of AML patients.

Importantly, we demonstrate that in Drosophila O-GlcNAcylation of LATS1 promotes the wing size. Thus, this study suggests that O-GlcNAcylation links extrinsic glucose levels to LATS1 in the Hippo pathway and cell proliferation.

Beyond mechanistic insights, this review critically evaluates the therapeutic potential of targeting the Hippo pathway, discussing innovative strategies such as small-molecule inhibitors, rational combinations with immunotherapy or chemo/radiotherapy, and the pathway's significant role in mediating drug resistance. Ultimately, this work aims to consolidate a theoretical foundation for developing novel, mechanism-based treatment strategies for CC, offering new perspectives and actionable targets for future clinical intervention.

Our findings establish DTX3L as: (1) a key molecular driver of RCC pathogenesis, (2) a regulator of the Hippo pathway via LATS2 modulation, and (3) a promising dual-purpose biomarker for RCC diagnosis and targeted therapy. This work provides the first evidence of DTX3L's oncogenic functions in RCC, offering new avenues for therapeutic development.

Our findings suggest that miR-135b overexpression in PCOS ovaries contributes to abnormal granulosa cell proliferation by inhibiting the Hippo pathway. This study enhances our understanding of ovarian abnormalities in PCOS and identifies miR-135b as a potential biomarker and therapeutic target for the disorder.

Treatment with a miR-31-5p mimic enhanced osteoclastogenesis by targeting large tumor suppressor kinase 2 (LATS2), whereas treatment with its inhibitor suppressed the sEV-mediated promotion of osteoclastogenesis. These findings reveal a mechanism by which TNF- and LPA-activated FLSs may facilitate sEV-mediated delivery of osteoclastogenic miRNAs, such as miR-31-5p, to osteoclast precursors, thereby contributing to osteoclast formation and bone destruction.

P1, N=137, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting

Owing to the fact that the Editorial Office has been made aware of potential issues surrounding the scientific integrity of this paper, we are issuing an Expression of Concern to notify readers of this potential problem while the Editorial Office continues to investigate this matter further. [International Journal of Oncology 48: 1997‑2006, 2016; DOI: 10.3892/ijo.2016.3405].

The presence of elevated pYAP expression may serve as a prognostic indicator of an aggressive OSCC with EMT during the invasive stage.